| Literature DB >> 30794547 |
Jonas Lanz1, Dörte Wyss2, Lorenz Räber1, Stefan Stortecky1, Lukas Hunziker1, Stefan Blöchlinger1, David Reineke2, Lars Englberger2, Thomas Zanchin1, Marco Valgimigli1, Dik Heg3,4, Stephan Windecker1, Thomas Pilgrim1.
Abstract
BACKGROUND: The study aims to assess characteristics and outcomes of patients suffering a mechanical complication (MC) after ST-segment elevation myocardial infarction (STEMI) in a contemporary cohort of patients in the percutaneous coronary intervention era. METHODS ANDEntities:
Mesh:
Year: 2019 PMID: 30794547 PMCID: PMC6386360 DOI: 10.1371/journal.pone.0209502
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flowchart.
2508 patients with ST-elevation myocardial infarction (STEMI) admitted for percutaneous coronary intervention at the University Hospital Bern between March 9, 2009 and June 30, 2014. 26 suffered a mechanical complication. STEMI, ST-elevation myocardial infarction; VSD, ventricular septal defect; VFWR, ventricular free wall rupture; PMR, papillary muscle rupture; * first patient lost to follow-up at day 26, second one at day 358; regarding non-lethal clinical endpoints.
Baseline characteristics.
| Mechanical complication | No mechanical complication | p-value | |
|---|---|---|---|
| Age (years) | n = 26, 74.5 ± 10.4 | n = 2482, 63.9 ± 13.1 | < 0.001 |
| Female gender | n = 26, 11 (42.3%) | n = 2482, 578 (23.3%) | 0.034 |
| Atrial fibrillation/flutter | n = 25, 2 (8.0%) | n = 1137, 65 (5.7%) | 0.651 |
| BMI (kg/m2) | n = 25, 26.3 ± 4.4 | n = 2271, 27.1 ± 4.4 | 0.371 |
| Cerebrovascular accident | n = 26, 2 (7.7%) | n = 2447, 95 (3.9%) | 0.272 |
| COPD | n = 26, 1 (3.8%) | n = 2447, 100 (4.1%) | 1.000 |
| Current Smoker | n = 25, 8 (32.0%) | n = 2402, 980 (40.8%) | 0.419 |
| Diabetes mellitus | n = 26, 7 (26.9%) | n = 2453, 384 (15.7%) | 0.169 |
| Gastrointestinal bleeding | n = 26, 0 (0.0%) | n = 2447, 35 (1.4%) | 1.000 |
| Hyperlipidemia | n = 26, 10 (38.5%) | n = 2428, 1118 (46.0%) | 0.554 |
| Hypertension | n = 26, 16 (61.5%) | n = 2441, 1313 (53.8%) | 0.554 |
| Peripheral artery disease | n = 26, 2 (7.7%) | n = 2442, 95 (3.9%) | 0.272 |
| Myocardial infarction | n = 26, 1 (3.8%) | n = 2447, 195 (8.0%) | 0.717 |
| PCI | n = 26, 1 (3.8%) | n = 2447, 220 (9.0%) | 0.724 |
| CABG | n = 26, 1 (3.8%) | n = 2449, 71 (2.9%) | 0.538 |
| Renal failure | n = 24, 16 (66.7%) | n = 1203, 225 (18.7%) | < 0.001 |
| LVEF (%) | n = 26, 46.9 ± 14.4 | n = 2407, 45.4 ± 11.9 | 0.506 |
| Anemia | n = 25, 12 (48.0%) | n = 1192, 207 (17.4%) | < 0.001 |
| Thrombocytopenia | n = 24, 5 (20.8%) | n = 1184, 12 (1.0%) | < 0.001 |
| Congestive heart failure | n = 26 | n = 2471 | < 0.001 |
| Killip I | 2 (7.7%) | 1776 (71.9%) | < 0.001 |
| Killip II | 4 (15.4%) | 358 (14.5%) | 0.783 |
| Killip III | 1 (3.8%) | 91 (3.7%) | 1.000 |
| Killip IV | 19 (73.1%) | 246 (10.0%) | < 0.001 |
The number of patients for whom data for the corresponding variable was available (denominator) is reported (n), followed by the number of patients fulfilling the criterion (counts (%)) for categorical variables or means ± standard deviation for continuous ones. P-values are derived from Fisher's exact or chi-square-tests for categorical and unpaired t-tests for continuous data. BMI, body mass index. COPD, chronic obstructive pulmonary disease. PCI, percutaneous coronary intervention. CABG, coronary artery bypass grafting. LVEF, left ventricular ejection fraction.
* derived from chi-square -test comparing all categories.
Coronary angiography: Lesion and procedural characteristics.
| Mechanical complication | No mechanical | p-value | |
|---|---|---|---|
| Symptom onset to balloon | n = 26 | n = 2466 | < 0.001 |
| 0–6 hours | 2 (7.7%) | 1189 (48.2%) | < 0.001 |
| 6–12 hours | 5 (19.2%) | 321 (13.0%) | 0.374 |
| 12–24 hours | 6 (23.1%) | 179 (7.3%) | 0.010 |
| <24 hours | 2 (7.7%) | 378 (15.3%) | 0.412 |
| >24 hours | 11 (42.3%) | 399 (16.2%) | 0.002 |
| PCI performed & completed | 13 (50.0%) | 2482 (100.0%) | < 0.001 |
| Number of lesions treated | 1.3 ± 0.9 | 1.6 ± 0.9 | 0.265 |
| Vessels treated | n = 17, | n = 3918, | 0.478 |
| LM | 0 (0.0%) | 90 (2.3%) | 1.000 |
| LAD | 4 (23.5%) | 1665 (42.5%) | 0.142 |
| LCX | 4 (23.5%) | 664 (16.9%) | 0.513 |
| RCA | 9 (52.9%) | 1465 (37.4%) | 0.213 |
| Bypass graft | 0 (0.0%) | 34 (0.9%) | 1.000 |
| Multivessel treatment | n = 13, 2 (15.4%) | n = 2482, 461 (18.6%) | 1.000 |
| Total occlusion | n = 17, 11 (64.7%) | n = 3884, 1716 (44.2%) | 0.140 |
| Pre TIMI flow | n = 17, | n = 3843, | 0.047 |
| 0 or 1 | 14 (82.4%) | 2013 (52.4%) | 0.014 |
| 2 | 1 (5.9%) | 650 (16.9%) | 0.336 |
| 3 | 2 (11.8%) | 1180 (30.7%) | 0.115 |
| Post TIMI flow | n = 17, | n = 3857, | 0.008 |
| 0 or 1 | 0 (0.0%) | 65 (1.7%) | 1.000 |
| 2 | 3 (17.6%) | 140 (3.6%) | 0.023 |
| 3 | 14 (82.4%) | 3652 (94.7%) | 0.059 |
| Any drug-eluting stent | n = 14, 13 (92.9%) | n = 3618, 3248 (89.8%) | 1.000 |
| Any bare-metal stent | n = 14, 1 (7.1%) | n = 3618, 378 (10.4%) | 1.000 |
| Total stent length (mm) | n = 14, 30.7 ± 14.2 | n = 3617, 27.7 ± 15.8 | 0.480 |
| IABP | n = 26, 14 (53.8%) | n = 2481, 115 (4.6%) | < 0.001 |
| Percutaneous LVAD | n = 26, 0 (0.0%) | n = 2145, 18 (0.8%) | 1.000 |
| Vasopressors | n = 26, 16 (61.5%) | n = 2479, 224 (9.0%) | < 0.001 |
| Unfractionated Heparin | n = 13, 12 (92.3%) | n = 2479, 2442 (98.5%) | 0.181 |
| LMWH | n = 13, 1 (7.7%) | n = 2478, 74 (3.0%) | 0.329 |
| GP IIb/IIIa | n = 13, 1 (7.7%) | n = 2478, 561 (22.6%) | 0.320 |
| P2Y12 loading dose | n = 13, 12 (92.3%) | n = 2482, 2423 (97.6%) | 0.272 |
Depicted are means (± SD) or counts (%) with p-values derived from unpaired t-tests for continuous and Fisher's exact or chi-square-tests for categorical data. PCI, percutaneous coronary intervention. LM, left main. LAD, left anterior descending. LCX, left circumflex. RCA, right coronary artery. TIMI, Thrombolysis In Myocardial Infarction. IABP, intra-aortic balloon pump. LVAD, left ventricular assist device. LMWH, low molecular weight heparin. GP, Glycoprotein.
* time to angiography for patients without PCI.
† derived from chi-square-test comparing all categories.
‡ exact onset time unknown.
§ in the registry only STEMI patients undergoing PCI are captured.
Mechanical complications: Management and 30-day mortality.
| N (%) | Management | 30-day mortality | ||||||
|---|---|---|---|---|---|---|---|---|
| Conservative | Inter-ventional | Surgery | N (%) | Conservative | Inter-ventional | Surgery | ||
| 26 | 9 (35%) | 3 | 14 | 15 (58%) | 9 (100%) | 3 | 3 | |
| Ventricular septal rupture (VSR) | 17 (65.4%) | 7 | 3 | 7 | 12 (71%) | 7 (100%) | 3 | 2 |
| Ventricular free wall rupture (VFWR) | 2 (7.7%) | 0 | 0 | 2 (100%) | 1 (50%) | 0 | 0 | 1 (50%) |
| VSR and VFWR | 2 (7.7%) | 2 (100%) | 0 | 0 | 2 (100%) | 2 (100%) | 0 | 0 |
| Papillary muscle rupture (PMR) | 5 (19.2%) | 0 | 0 | 5 (100%) | 0 (0%) | 0 | 0 | 0 (0%) |
Depicted are counts (percentages). The percentages shown for the management categories refer to the total number of patients pertaining to the specific complication types. The reported percentages of patients dying within 30 days refer to the number of patients in the different management categories stratified by complication type. N, number.
* In two patients the attempt to implant an occluder device was unsuccessful.
† Three patients, who received an occluder device, but consecutively underwent surgery, are assigned to the surgical group and not included in the interventional group; two of them survived, one died.
Fig 2Survival curves.
Depicted are survival curves for all-cause mortality based on the product-limit estimator comparing patients with and patients without a mechanical complication in the context of an ST-elevation myocardial infarction.